VIP

Vasoactive Intestinal Peptide is a 28-amino-acid neuropeptide utilized primarily for immune modulation, inflammation management, and neuroprotection. Users typically run daily doses ranging from 25 µg to 200 µg, with 100 µg serving as the community modal dose, while clinician-led protocols often utilize 200 µg daily. Prospective users should note that the off-label evidence base is significantly thinner than common discourse suggests, as most exploratory indications lack posted results. Additionally, the registered trial program shows a 19% withdrawal rate, and while rare, users occasionally report experiences involving sleep disturbances, fluid retention, or gastrointestinal discomfort.

Half-life~1 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.63.42.83.23.02.0

Research Evidence

Evidence shape

VIP possesses high-tier evidence primarily centered on diagnostic and mechanistic research, supported by a broad landscape of 16 registered trials. While the literature includes Phase 3-grade data and 17 linked publications, the clinical breadth remains thin, with only two of 14 mapped indications yielding posted results. The research pipeline shows significant fragmentation, characterized by a high volume of single-trial, long-tail investigations across diverse conditions like respiratory failure and migraine, alongside a 19% trial withdrawal rate that signals limited maturity for most therapeutic applications.

Depthhow much
16 registered trials
11 completed · 2 with posted results · 1 recruiting / active · combined n=676
Breadthhow many areas
14 indications mapped
2 with results · 10 thin / exploratory · 1 animal-only · 10 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
2 blinded with results · 8 distinct sponsors · 19% withdrawal rate · AE table from NCT04311697 · 17 linked publications on registered trials
Breadth and depth30 rows captured
Human
direct clinical signal
17
Animal
translational support
12
In vitro
mechanistic support
1
HighMediumLow

Anecdotal efficacy

VIP side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Uther
unknown
100 mg×10
$140.00
$1.4/mg
2
Peptide Pros
--
5 mg
$7.50
$1.5/mg
3
Saiyan Med
US
100 mg×10
$180.00
$1.8/mg
4
Chimera Peptides
CN
100 mg×10
$217.00
$2.17/mg
5
BulkGLP
USA
1000 mg
$2,263.00
$2.26/mg
6
peptidesourcehub.com
CN
100 mg
$234.90
$2.35/mg

price offers can be sorted by column · 11 out-of-stock offers not shown

1-6 of 118

VIP dosing & protocol

How VIP is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 11
weight-based
Typical dose
—
0
50 µg
100 µg
150 µg
200 µg
across 1 dosed source · darker = more agree
Frequency
daily
Route
IV

In research trials, VIP was given at 1000 mg per square meter of body surface area, administered intravenously each day.

11 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
200 µg
typical
0
50 µg
100 µg
150 µg
200 µg
across 1 dosed source · darker = more agree
By reported cadence
Daily200 µg · n=1
Frequency
daily
Route
IV

The sole source, the Peptide List, reports a dose of 200 mcg of VIP delivered intravenously once per day for clinicians.

1 source
Anecdotal
Community-reported real-world use · n = 5
Typical dose
100 µg25 µg – 200 µg
typical
0
50 µg
100 µg
150 µg
200 µg
distribution of 6 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
intranasal

Daily dosing (≈100 mcg, n=2) and an unspecified schedule (≈200 mcg, n=2) are each reported by two users, while a smaller group doses weekly (≈100 mcg, n=1).

5 sources

Related peptides

ThymalinLL-37Thymosin Alpha-1Thymulin